- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06006416
Effect of Fenugreek Fibre on Gut Microbiome
November 16, 2023 updated by: RDC Clinical Pty Ltd
Effect of Fenugreek Fibre (Trigonella Foenum-graecum) on the Gut Microbiome in an Adult Population - An Open Label, Self-controlled Trial
A open label, self-controlled trial to evaluate the effect of Fenugreek Fibre (Trigonella foenum-graecum) on the gut microbiome in generally healthy adults aged 18-65 years old.
Study Overview
Study Type
Interventional
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Amanda Rao, PhD
- Phone Number: +61 414 488 559
- Email: amanda@rdcglobal.com.au
Study Contact Backup
- Name: David Briskey, PhD
- Phone Number: +61 421 784 077
- Email: david@rdcglobal.com.au
Study Locations
-
-
Queensland
-
Brisbane, Queensland, Australia, 4006
- RDC Global Pty Ltd
-
Contact:
- Amanda Rao, PhD
- Phone Number: +61 414 488 559
- Email: amanda@rdcglobal.com.au
-
Contact:
- David Briskey, PhD
- Phone Number: +61 421 784 077
- Email: david@rdcglobal.com.au
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Male and females aged 18-65 years old
- Generally healthy
- Able to provide informed consent
- BMI > 25kg/m2
- Agree not to participate in another clinical trial while enrolled in this trial
- Agree not the change their diet or exercise while enrolled in this trial
Exclusion Criteria:
- Unstable(1) or serious illness (e.g. kidney, liver, GIT, heart conditions, diabetes, thyroid gland function, lung conditions, chronic asthma and mood disorders or neurological disorders such as MS)
- Current malignancy (excluding BCC) or chemotherapy or radiotherapy treatment for malignancy within the previous 2 years
- Currently taking Coumadin (Warfarin), Heparin, Dalteparin, Enoxaparin or other anticoagulation therapy
- Acute sickness experienced within the past 2 months
- Current use of medications (e.g. antibiotics) or supplements (e.g. pre- and probiotics) that alter the microbiome or gut health. Any use during the trial will result in exclusion from the study.
- Active smokers and/or nicotine or drug abuse
- Chronic alcohol use (>14 alcoholic drinks week)
- Allergic to any of the ingredients in the formula
- Pregnant(2) or lactating woman
- Females of child bearing potential not using a highly effective form of contraception(3,4) (i.e. methods which result in low failure rate, i.e. less than 1% per year, when used consistently and correctly like the oral contraception pill, birth control implant e.g. implanon(3,4))
- People medically prescribed medications that would affect the immune and/or the inflammatory response (e.g. NSAIDs, steroids, antibiotics).
- Any condition which in the opinion of the investigator makes the participant unsuitable for inclusion
- Participants who have participated in any other related clinical study during the past 1 month
- People with cognitive damage
- People who have or have had treatment for cancer, HIV or chronic use of any dose of steroids (cream, tablet or inhalant) in the past year
Footnotes
- An unstable illness is any illness that is currently not being treated with a stable dose of medication or is fluctuating in severity. A serious illness is a condition that carries a risk of mortality, negatively impacts quality of life and daily function and/or is burdensome in symptoms and/or treatments.
- All female participants of child bearing potential will be required to take a urine pregnancy test prior to entry into the study.
- Examples of acceptable forms of highly effective contraception include: Established use of oral, injected or implanted hormonal methods of contraception; Placement of an intrauterine device (IUD) or intrauterine system (IUS); Sterilised male partner (with the appropriate post-vasectomy documentation of the absence of sperm in the ejaculate); True abstinence: When this is in line with your preferred and usual lifestyle
- Examples of non-acceptable methods of contraception include: Condoms alone or double barrier; Periodic abstinence (e.g. calendar, ovulation, symptothermal, post ovulation); Withdrawal; Spermicide (as it is not approved as a method of contraception in Australia)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Fenugreek Fibre
Fenugreek Fibre - 2 x 10g powder per day with/in food
|
Daily dose of 2 x 10g per day with/in food
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in metagenomic profile of the gut microbiome
Time Frame: Week 0, week 4 and week 16
|
Change in metagenomic profile of the gut microbiome as measured by 16s rRNA gene sequencing
|
Week 0, week 4 and week 16
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in gut function
Time Frame: Week 0, week 4 and week 16
|
Change in gut function as measured by faecal short change fatty acids testing via faecal sample
|
Week 0, week 4 and week 16
|
Change in intestinal permeability
Time Frame: Week, 0, week 4, week 8 and week 16
|
Change in intestinal permeability as measured by plasma occludin, Muc2 and Endotoxin via blood test
|
Week, 0, week 4, week 8 and week 16
|
Change in gut inflammation
Time Frame: Week 0, week 4 and week 16
|
Change in gut inflammation as measured by faecal calprotectin via faecal sample
|
Week 0, week 4 and week 16
|
Change in inflammation
Time Frame: Week, 0, week 4, week 8 and week 16
|
Change in inflammation as measured by inflammatory markers (IFN-g, TNF-a, il-2, MCP-2, IL-1b, TGF-b, CRP) via blood test
|
Week, 0, week 4, week 8 and week 16
|
Change in GLP-1
Time Frame: Week, 0, week 4, week 8 and week 16
|
Change in GLP-1 as measured by blood test
|
Week, 0, week 4, week 8 and week 16
|
Change in GST
Time Frame: Week, 0, week 4, week 8 and week 16
|
Change in GST as measured by blood test
|
Week, 0, week 4, week 8 and week 16
|
Change in glutathione
Time Frame: Week, 0, week 4, week 8 and week 16
|
Change in glutathione as measured by blood test
|
Week, 0, week 4, week 8 and week 16
|
Change in FABP
Time Frame: Week, 0, week 4, week 8 and week 16
|
Change in FABP as measured by blood test
|
Week, 0, week 4, week 8 and week 16
|
Change in Homocysteine
Time Frame: Week, 0, week 4, week 8 and week 16
|
Change in Homocysteine as measured by blood test
|
Week, 0, week 4, week 8 and week 16
|
Change in diet
Time Frame: Week 0 and Week 16 (completed for 3 consecutive days)
|
Change in diet as measured by 24hr Dietary Recall
|
Week 0 and Week 16 (completed for 3 consecutive days)
|
Change in quality of life
Time Frame: Week, 0, week 4, week 8 and week 16
|
Change in quality of life as measured by the SF-36 questionnaire.
Consists of eight scaled scores, which are the weighted sums of the questions in their section.
Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight.
The lower the score the more disability.
|
Week, 0, week 4, week 8 and week 16
|
Change in stress state
Time Frame: Week, 0, week 4, week 8 and week 16
|
Change in stress as measured by the Perceived Stress Scale questionnaire.
Consists of 10 items with a score range 0-40.
Higher scores indicate higher perceived stress.
|
Week, 0, week 4, week 8 and week 16
|
Change in sleep quality
Time Frame: Week, 0, week 4, week 8 and week 16
|
Change in sleep as measured by the Leeds Sleep Evaluation Questionnaire.
Consists of ten questions pertaining to four consecutive aspects of sleep: getting to sleep (GTS), quality of sleep (QOS), awakening from sleep (AFS), and behaviour following wakefulness (BFW).
Higher scores indicate better sleep quality.
|
Week, 0, week 4, week 8 and week 16
|
Change in safety
Time Frame: Week 0, week 4 and week 16
|
Change in safety as measured by E/LFT via blood test
|
Week 0, week 4 and week 16
|
Height
Time Frame: Week 0, week 4 and week 16
|
Height as measured by stadiometer
|
Week 0, week 4 and week 16
|
Change in weight
Time Frame: Week 0, week 4 and week 16
|
Change in weight as measured by digital scale
|
Week 0, week 4 and week 16
|
Change in hip and weight circumference
Time Frame: Week 0, week 4 and week 16
|
Change in hip and weight circumference as measured by tape measure
|
Week 0, week 4 and week 16
|
Change in blood pressure
Time Frame: Week 0, week 4 and week 16
|
Change in blood pressure as measured by blood pressure monitor
|
Week 0, week 4 and week 16
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Amanda Rao, PhD, RDC Clinical Pty Ltd
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
September 1, 2023
Primary Completion (Estimated)
May 1, 2024
Study Completion (Estimated)
September 1, 2024
Study Registration Dates
First Submitted
August 1, 2023
First Submitted That Met QC Criteria
August 22, 2023
First Posted (Actual)
August 23, 2023
Study Record Updates
Last Update Posted (Estimated)
November 20, 2023
Last Update Submitted That Met QC Criteria
November 16, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Other Study ID Numbers
- FENGUT
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gut Microbiome
-
University of California, DavisCompletedGut Microbiome | Skin Microbiome | Gut Lipidome | Skin Lipidome | Blood LipidomeUnited States
-
ProgenaBiomeRecruitingGastrointestinal Microbiome | Gut MicrobiomeUnited States
-
University College CorkAIT Austrian Institute of Technology GmbHNot yet recruiting
-
Evolve BioSystems, Inc.University of California, DavisCompletedGut MicrobiomeUnited States
-
State University of New York at BuffaloCompleted
-
Access Business GroupCompletedGut MicrobiomeUnited States
-
Washington University School of MedicineCompleted
-
Evolve BioSystems, Inc.Terminated
-
Evolve BioSystems, Inc.CompletedInfant Gut MicrobiomeUnited States
-
University of Colorado, DenverNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingGut Microbiome | Linear GrowthUnited States
Clinical Trials on Fenugreek Fibre
-
University of GuelphAgriculture and Agri-Food Canada; Natural Sciences and Engineering Research... and other collaboratorsCompletedType 2 Diabetes MellitusCanada
-
Jacksonville UniversitySPECNOVA LLCCompletedAging | Testosterone DeficiencyUnited States
-
GlaxoSmithKlineCompletedImpaired Fasting GlucoseIndia
-
University of Veterinary and Animal Sciences, Lahore...Completed
-
King's College LondonDanone Nutricia ResearchCompletedFunctional Bloating (Disorder)United Kingdom
-
University of Mary Hardin-BaylorIndus Biotech Ltd. Pvt.CompletedInflammation | Muscle DamageUnited States
-
University of RoehamptonRecruiting
-
German Institute of Human NutritionUmeå University; VTT Technical Research Centre of Finland; Quadram Institute...CompletedBlood Markers | Intestinal Microbiota
-
DaniscoCompletedHealthy VolunteersUnited Kingdom
-
University College CorkRecruiting